<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00644306</url>
  </required_header>
  <id_info>
    <org_study_id>University Hospital, Nancy</org_study_id>
    <nct_id>NCT00644306</nct_id>
  </id_info>
  <brief_title>Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (&gt; 75 Years) With Multiple Myeloma</brief_title>
  <acronym>IFM 01/01</acronym>
  <official_title>Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (&gt; 75 Years) With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been
      usedsince the 1960s and is regarded as the standard of care in very elderly patients. We
      assess whether the addition of thalidomide at 100 mg/day to this combination would improve
      survival.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    survival advantage demonstrated
  </why_stopped>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall Survival</measure>
    <time_frame>May 2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>May 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>May 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>May 2007</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Newly Diagnosed, Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>100 mg/day continuously for 18 months</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan, prednisone</intervention_name>
    <description>12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Alkeran, cortancyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan, prednisone, thalidomide</intervention_name>
    <description>12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Alkeran, cortancyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage II or III multiple myeloma according to Durie and Salmon criteria, patients
             older than 75 years, previously untreated patients.

        Exclusion Criteria:

          -  Prior history of another neoplasm (except basocellular cutaneous or cervical
             epithelioma)

          -  Primary or associated amyloïdosis

          -  World Health organisation performance index of at least 3

          -  Significant renal insufficiency with creatinine serum levels of 5.0 mg per deciliter
             or more

          -  Cardiac or hepatic dysfunction

          -  Cerebral circulatory insufficiency

          -  Absolute contraindication to corticosteroids

          -  Peripheral neuropathy clinically significant

          -  History of venous thrombosis during the last 6 months

          -  HIV or hepatitis B or C positivity

          -  Patients who had geography, social, or psychological conditions which might prevent
             adequate follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyrille Hulin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology CHU Nancy and Intergroupe Francophone du Myelome (IFM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Nancy - Brabois, rue du morvan</name>
      <address>
        <city>Vandoeuvre</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007 Oct 6;370(9594):1209-18.</citation>
    <PMID>17920916</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>March 20, 2008</last_update_submitted>
  <last_update_submitted_qc>March 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Hulin Cyrille</name_title>
    <organization>Intergroupe Francophone du Myélome (IFM)</organization>
  </responsible_party>
  <keyword>Multiple Myeloma, very elderly patients, thalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

